
New Strong Sell Stocks for January 27th
DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.
Loading news...

DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.

WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Annual Meeting”) on March 23, 2026 at 10:00 a.m. Eastern Time, in virtual-only format at https://www.cstproxy.com/nrxpharma/2026, and any adjournments or postponements thereof. The Company's Board of Directors (the “Board”) also set a record date of February 12, 2026 entitling stockholders of record as of such date to notice of and to vote at the 2025 Annual Meeting.

WILMINGTON, Del., Jan. 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has licensed Real World Evidence (RWE) drawn from over 70,000 patients in the United States who were treated with either intravenous ketamine or nasal S-ketamine for depression and suicidal ideation. The information is being submitted in support of NRx's application for Accelerated Approval of NRX-100 (preservative-free ketamine) under Fast Track Designation for Treatment of Suicidal Ideation in Depression and Bipolar Depression. Currently, there is no medicine approved to treat suicidal ideation and the only FDA-approved treatment today is Electroshock Therapy.

NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) and Universe Pharmaceuticals (NASDAQ: UPC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Profitability This table compares NRx Pharmaceuticals and

WILMINGTON, Del. and MUNICH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company and neurocare Group AG today (“The Partners”) announced a partnership to create a nationwide network of clinics to offer integrated neuroplastic care for the treatment of Depression, PTSD, and other serious mental health disorders. Pilot programs have shown that combining Transcranial Magnetic Stimulation (TMS) with ketamine and other neuroplastic drugs, along with hyperbaric oxygen therapy and supportive psychotherapy has resulted in a high rate of remission among First Responders with PTSD and Depression.

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on

Salarius Pharmaceuticals (NASDAQ: SLRX - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Analyst Ratings This is a breakdown of

WILMINGTON, Del., Dec. 18, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has repaid the remaining $5.4 million balance sheet debt to Anson Funds, LLC, through equity conversion of common stock. There were no warrants or other repricing mechanisms associated with this transaction. Anson originally lent $16.2 million USD to the Company to fund repayment of prior loans and corporate operating expenses. With this repayment, the Company anticipates ending the 2025 calendar year with a balance sheet free of all debt. NRx believes that this milestone properly positions the company's capital structure for accelerated growth with anticipated drug approvals and clinic expansions in the coming year.

USANA Health Sciences (NYSE: USNA - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Volatility and Risk USANA Health Sciences

Shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation

WILMINGTON, Del., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has amended its Investigational New Drug filing for NRX-101 (D-cycloserine/lurasidone) to include the use of NRX-101 in association with Transcranial Magnetic Stimulation (TMS) for the treatment of depression, including suicidal depression.

NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript

WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has received the Company's Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free intravenous ketamine formulation. The acknowledgement letter states that the FDA has “made a threshold determination that this ANDA is substantially complete” and issued a goal date of July 29, 2026 for completion of the final review with potential marketing approval.

WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a corporate update conference call on Tuesday, December 2, 2025 at 9:00am ET.

WILMINGTON, Del., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, the “Company”, “NRx”), a clinical-stage biopharmaceutical company and HOPE Therapeutics, an interventional psychiatry network owned by NRx, today announced that its Founder, Chairman, and Chief Executive Officer, Jonathan Javitt, M.D.

NRx Pharmaceuticals, Inc. ( NRXP ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Matthew Duffy - Chief Business Officer & Co-CEO of Hope Therapeutics Michael Abrams - Chief Financial Officer Jonathan Javitt - Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Conference Call Participants Thomas Shrader - BTIG, LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals' Q3 2025 Earnings Conference Call.

NRx has refiled its Abbreviated New Drug Application for KETAFREE™ (preservative free ketamine), received supportive correspondence from FDA, and expects Q2 2026 GDUFA date. HOPE Therapeutics is now operating three revenue-generating facilities in Florida and expects six or more by year-end providing neuroplastic drugs, transcranial magnetic stimulation, hyperbaric therapy, and digital therapeutics to treat suicidal depression and PTSD.

WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2025 financial results before the market opens on Monday, November 17, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 8:30am ET the same day.

SARASOTA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) today announced initiation of patient care with for treatment-resistant depression with the Ampa one day (ONE-D) protocol. HOPE is the first to deploy the Ampa technology in Florida and one of the first deployments nationwide. The Ampa device differs from other Transcranial Magnetic Stimulation (TMS) treatments in that the peer-reviewed literature has reported a high rate of success (87% response and 72% remission) in nonrandomized trials when a single day of TMS treatment is combined with physician-prescribed D-cycloserine and lisdexamfetamine (note that neither of the drugs reported in the published results is FDA-approved for the stated indication).1 D-cycloserine was previously reported to substantially enhance the effectiveness of TMS in reducing depression and suicidality by more than two-fold in a placebo-controlled trial using a traditional TMS protocol.2 Additional supportive findings documenting the effect of D-cycloserine in enhancing the effect of TMS were recently published by a team of researchers led by Prof. Joshua Brown at Harvard's McLean hospital.3 Dr. Brown additionally serves as the President of the Clinical TMS Society.

MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), today announced the acquisition of a strategic interest in Cohen and Associates, LLC (“Cohen, LLC”) and its incorporation into the HOPE Network. Additionally, Rebecca Cohen, MD has joined HOPE as Medical Director, overseeing medical standards of care throughout HOPE's Florida locations.